What is Shandong Boan Biotechnology Co Operating Cash Flow per Share?
Shandong Boan Biotechnology Co's operating cash flow per share for the
six
months ended in Dec. 2023 was HK$0.02.
Shandong Boan Biotechnology Co's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.04.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 67.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Shandong Boan Biotechnology Co's Operating Cash Flow per Share or its related term are showing as below:
HKSE:06955'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 67.6 Med: 67.6 Max: 67.6
Current: 67.6
During the past 4 years, Shandong Boan Biotechnology Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.60% per year. The lowest was 67.60% per year. And the median was 67.60% per year.
HKSE:06955's 3-Year OCF Growth Rate is ranked better than 96.27% of 1234
companies
in the Biotechnology industry
Industry Median: 3.5
vs HKSE:06955: 67.60
Shandong Boan Biotechnology Co Operating Cash Flow per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shandong Boan Biotechnology Co Operating Cash Flow per Share Chart
Competitive Comparison of Shandong Boan Biotechnology Co's Operating Cash Flow per Share
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's Price-to-Operating-Cash-Flow falls into.
Shandong Boan Biotechnology Co Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Shandong Boan Biotechnology Co's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Shandong Boan Biotechnology Co (HKSE:06955) Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06955 has been successfully added to your